![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Celltrion Launches Phase 1 Trial of Investigational COVID-19 Antiviral
Celltrion Launches Phase 1 Trial of Investigational COVID-19 Antiviral
![COVID-19 Clinical Trial](https://www.fdanews.com/ext/resources/test/Drug-Images4/COVID-19-CLINICAL-TRIAL.gif?t=1585696642&width=430)
July 20, 2020
Celltrion has launched a phase 1 clinical trial in Korea of its investigational antiviral antibody treatment for COVID-19 patients.
The trial will evaluate the drug’s safety in 32 healthy volunteers who have not been diagnosed with COVID-19.
Celltrion is also set to conduct a phase 1 trial of its antiviral to treat mild COVID-19 patients in Europe, along with a separate study to assess the drug’s potential as a preventative treatment.
Upcoming Events
-
21Oct